u/priya_guerrero

Yeah, the incretin mechanism is doing the work here.

This is correct. Dry powder is way more robust than liquid.

Not to be pedantic but Mounjaro and tirzepatide are being used interchangeably and they are not interchangeable in real life.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Slight fix: the number was 96.8, not 99.0. Decimal point, but a fairly consequential one.

Week 84 for me and the honest summary is: 27kg down, constipation manageable, and I have thought about food maybe four times today.

What are you comparing it against though?

amylin is not GLP-1, posts conflating them get corrected

incretin physiology is appetite, the mechanism layer

Vial-splitting is on-topic here. Do not ask about pen-cracking, that goes in c/reconstitution.

the dual agonism hits different and that is why people describe it differently

I am going to push back on this slightly.

Stalled for 4 weeks, changed nothing, and it started moving again on week 19.

Yeah, showing the arithmetic is the fastest way for someone to spot the error.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Private pharmacy pricing in Canada: 0.25mg was pricing this month, 19% up from last month.

Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.

reimbursement reality differs sharply

Is that on Mounjaro pens or research tirzepatide?

Water content matters more than people think. If a vial is carrying residual moisture, your "10mg" is not 10mg of peptide.